Anshumi Desai

Anshumi Desai

Auto-generated profile, based on publicly available information

Anshumi Desai

University of Miami Miller School of Medicine Miami Florida USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
TPTatiana C. Pelegrina Perez
Tatiana C. Pelegrina Perez
ADAnshumi Desai
Anshumi Desai
KTKashyap K. Tadisina
Kashyap K. Tadisina
DSDevinder P. Singh
Devinder P. Singh
SKSusan B. Kesmodel
Susan B. Kesmodel
JMJuan R. Mella-Catinchi
Juan R. Mella-Catinchi

1 January 2024 in The Breast Journal
Verified
Journal Article
Open access
EBEduarda Bustamante
Eduarda Bustamante
FCFresia Casas
Fresia Casas
RLRenato Luque
Renato Luque
LPLuis Piedra
Luis Piedra
SBShamir Shamir Barros Barros-Sevillano
Shamir Shamir Barros Barros-Sevillano
JAJhajaira Araujo
Jhajaira Araujo
Background. Breast cancer is an important cause of cancer‐related death in women worldwide and represents the second most frequent cause of brain metastases after lung cancer. The aim of this study was to determine the characteristics and outcomes of triple‐negative breast cancer (TNBC) patients with brain metastasis (BM). Methods. We retrospectively reviewed a cohort of patients diagnosed with TNBC at the “Instituto Nacional de Enfermedades Neoplasicas” (period 2000–2014) to evaluate patients who developed BM. Survival rates were assessed by the Kaplan–Meier method, and prognostic factors were identified with the Cox regression analysis. Results. Of a total of 2007 TNBC patients, 193 (9.62%) developed BM. Of these, 169 stages I–III patients with a median age of 45 years (range:21–78) were included. The stage in this cohort was 4 (2.4%) clinical stage (CS) I, 23 (13.6%) with CS II and 142 (84.0%) with CS III. Most of these patients presented ECOG ≥2 (68.6%). The most common symptom was headache (74.0%), followed by nausea‐vomiting (46.7%). Imaging showed that 80 patients (53.0%) had ≥1 metastatic brain lesion. Regarding the treatment of BM in this cohort, 132 patients (84.6%) received radiotherapy (RT), 2 (1.5%) surgery, and 6 (4.5%) surgery plus RT. The overall survival (OS) rate of BM was 59.8%, 37.3%, and 15.0% at 3, 6, and 12 months, respectively. A multivariate analysis showed RT to be the only factor with a positive impact on the OS of BM (hazard ratio (HR) = 0.48, 95% confidence interval (CI):0.30‐0.77, and p = 0.002), while ECOG ≥2 was associated with a worse OS (HR = 1.69, 95%CI:1.15–2.48, and p = 0.007). Conclusion. Despite the poor prognosis of TNBC patients who develop BM, RT showed a benefit in OS rates, while ECOG ≥2 was the only prognostic factor associated with a worse OS. These results may be useful for multidisciplinary teams for treatment planning in patients with TNBC and BM.

1 January 2025 in The Breast Journal
Verified
Journal Article
Open access
ADAnshumi Desai
Anshumi Desai
SKSusan B. Kesmodel
Susan B. Kesmodel
BSBarbara Susnik
Barbara Susnik
NGNeha Goel
Neha Goel
YFYara Feliciano
Yara Feliciano
YTYouley Tjendra
Youley Tjendra
Background: Florid lobular carcinoma in situ is an uncommon lobular neoplasia variant that is frequently associated with invasive carcinoma. However, there remains a paucity of information to guide management. The authors aimed to study imaging features associated with pathologic upgrade rates for patients with florid lobular carcinoma in situ identified on core biopsy undergoing surgical excision. Methods: Patients with florid lobular carcinoma in situ on core biopsy were selected from an institutional pathology database. Patients were excluded if pleomorphic lobular carcinoma in situ was also present on core biopsy. Clinical, radiologic, and pathologic features for each case were reviewed focusing on imaging features which led to core biopsy and those associated with pathologic upgrade on surgical excision. Results: Eighteen cases of florid lobular carcinoma in situ underwent surgical excision. Upgrade rates on surgical excision were higher in cases with suspicious calcifications (8/11, 73%, p = 0.049) compared to those without (1/7, 14.3%) and in cases with larger breast lesions ( p = 0.011). The overall upgrade rate was 50% (9/18), 89% (8/9) with invasive lobular carcinoma and 11% (1/9) with ductal carcinoma in situ. Of the 8 cases with upgrade to invasive lobular carcinoma, 7/8 (87.5%) were Stage I cancers and only 1/8 (12.5%) had macroscopic lymph node involvement and was upgraded to Stage II. Conclusion: Florid lobular carcinoma in situ on core biopsy had an upgrade rate on surgical excision of 50% overall, with 89% of these cases upgraded to invasive lobular carcinoma. Pathologic upgrade was seen more frequently with suspicious calcifications and larger breast lesions. These findings can help guide surgical management of this uncommon lobular neoplasia variant including planning extent of excision and consideration for lymph node evaluation.

4 September 2024 in Surgery
Verified
Journal Article
Closed access
ADAnshumi Desai
Anshumi Desai
VDVictoria Dahl
Victoria Dahl
ISIago De Castro Silva
Iago De Castro Silva
MCMeaghan Clark
Meaghan Clark
KXKyle Y. Xu
Kyle Y. Xu
JMJuan R. Mella-Catinchi
Juan R. Mella-Catinchi

30 December 2023 in The Surgeon
Verified
Journal Article
Closed access
GKGabriel De la Cruz Ku
Gabriel De la Cruz Ku
ADAnshumi Desai
Anshumi Desai
ANAlexis R. Narvaez-Rojas
Alexis R. Narvaez-Rojas
CZCaiwei Zheng
Caiwei Zheng
ACAmber Collier
Amber Collier
MMMecker G Möller
Mecker G Möller

10 January 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Open access
PDF file
ADAnshumi Desai
Anshumi Desai
TSTaylor Smartz
Taylor Smartz
OTOrel Tabibi
Orel Tabibi
PBPeter A. Borowsky
Peter A. Borowsky
KTKashyap Komarraju Tadisina
Kashyap Komarraju Tadisina
JMJuan R. Mella-Catinchi
Juan R. Mella-Catinchi
Introduction: Silicone Lymphadenopathy (SL) is a complication of breast implants that involves migration of silicone to nearby soft tissue/lymph nodes. Data on its clinical features and management is scarce. We aimed to identify the clinical presentation and management of SL. Methods: A single-institution retrospective cohort study was conducted from our institutional imaging system where search terms “Silicone lymphadenopathy”, “silicone adenitis” and “silicone adenopathy” were used to identify patients with SL (January 2016–September 2023). Patient demographics, clinical features, imaging findings, pathological investigation, and treatment were obtained from the medical records. Results: Of 52 patients with SL, breast augmentation accounted for 90.4% of the implant placements. All patients had silicone implants placed at some time. A significant portion of patients (69.3%) were asymptomatic, while 7.7% had non-tender lymphadenopathy, 19.2% experienced painful lymphadenopathy, and 1.9% presented with mixed symptoms. Implant rupture was observed in 88.7% of cases; 13.0% intracapsular, 26.1% extracapsular, 15.2% both, and unknown in 45.7%. Axillary nodes were the most commonly involved (86.5%), and ultrasonography was most commonly used to detect SL (80.7%). Biopsy was performed in 17.3% of cases, confirming benign pathology in all cases. No patients required surgical excision of lymph nodes for management of SL. Conclusion: Most patients with SL are asymptomatic and are managed with observation. Biopsy and surgical intervention should be reserved for those patients with abnormal imaging or persistent symptoms. Evaluation of lymphadenopathy is essential to exclude malignancy in patients with a history of breast cancer. Level of Evidence III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.